Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model

@inproceedings{Nguyen2014TargetingAO,
  title={Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model},
  author={H G Nguyen and J C Yang and H-J Kung and X Shi and Derya Tilki and Primo N. Lara and Ralph W. deVere White and Allen C Gao and Christopher P Evans},
  booktitle={Oncogene},
  year={2014}
}
Macro-autophagy is associated with drug resistance in various cancers and can function as an adaptive response to maintain cell survival under metabolic stresses, including androgen deprivation. Androgen deprivation or treatment with androgen receptor (AR) signaling inhibitor (ARSI), Enzalutamide (MDV-3100, ENZA) or bicalutamide induced autophagy in androgen-dependent and in castration-resistant CaP (castration-resistant prostate cancer (CRPC)) cell lines. The autophagic cascade triggered by AR… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 49 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 41 references

Autophagy and prostate cancer therapeutics

  • H-J Kung, HG Nguyen, JC Yang, CP Evans, RJ Bold, F. Chuang
  • Prostate Cancer
  • 2013

of hormone - resistant prostate cancer cells and confer resistance to apoptosis

  • M Korpal, JM Korn, X Gao, DP Rakiec, DA Ruddy, S Doshi
  • 2013

Similar Papers

Loading similar papers…